China's Strong Economic Growth and Healthcare Investments Generate Success for CPhI
Amsterdam (ots/PRNewswire)
China's 'Five Year Plan' underway as attendance at 2013 show rockets
CPhI and UBM Live today announced that this year's recent CPhI China 2013, which took place on 25th-27th June at the Shanghai New International Expo Centre, was the most successful exhibition to date.
(Logo: http://photos.prnewswire.com/prnh/20130723/629764-a )
Attendance rates far exceeded expectation and CPhI and P-MEC China, alongside co-located events BioPh, ICSE, InnoPack, hosted a record breaking more than 2,400 companies, both local and international, and attracted more than 30,000 visitors from 133 countries throughout the world.
The 13th consecutive event was the foremost meeting point and networking opportunity for senior Chinese pharma professionals and international pharmaceutical suppliers and buyers.
In response to the implementation of China's 'five year plan', CPhI China 2013 saw a strong focus on research and development with LABWorld, BioPharma and ICSE all contained in one hall, mirroring China's continued commitment to this area and reflecting its exemplary position in the pharmaceutical world.
R&D investments in China have been at a high throughout 2013- it has been estimated that growth in investment within this area matches that of the USA. The [12th] 'Five-Year Plan', implemented by the Chinese government targets pharmaceutical R&D as a key initiative, with financial and beneficial incentives being offered in order to encourage R&D activities within the country. These include exemption from import customs duty on R&D equipment and a reduced income tax rate. In light of this, the R&D focus at CPhI China 2013 provided an informative update on the efforts being made by the government in facilitating innovation within the country.
On-site at CPhI China 2013, the "China and World" Medical Forum proved highly insightful and valuable for attendees. Having received substantial support from a vibrant speaker team of government and leading pharmaceutical companies, the forum showcased hot topic seminars and conferences. These covered the latest policies and regulations within the pharmaceutical industry and the practical applications of new technology. Furthermore, the Buyer Sourcing Event, with more than 60 buyers, 280 sessions and over 90% successful match rate, has provided a catalyst for increased business connections in the region.
Chris Kilbee, CPhI Pharma Group Director at UBM Live commented, "The Chinese pharmaceutical industry is now the third largest in the world and is ever growing -- it is predicted to expand at the annual rate of 12% from 2013 to 2020. Having witnessed a shift in focus to R&D by China, CPhI China 2013 was designed to reflect these widespread changes. The event was undoubtedly a success for both UBM Live, CCMHPIE and our attendees and, consequently, over 40% of exhibitors present have already registered for next year. This result shows that CPhI China is now at the centre of pharmaceutical business connections within the region."
CPhI 2014 will return alongside co-located events ICSE, BioPh, P-MEC, InnoPack and Labworld, on 26th -28th June, 2014 at the Shanghai New International Expo Centre. The exhibition will increase its scale and, reiterating the importance of R&D in China as CPhI China 2014 will focus on biopharmaceutical R&D with 'BioPh China' and 'ICSE China' making up an integral part of the exhibition. A further main focus for next year will be natural extracts in which exhibiting companies will occupy more than one hall.
The UBM Live annual schedule of Pharmaceutical events also includes CPhI Worldwide, ICSE, P-MEC Europe and InnoPack ; CPhI and P-MEC India (03-05 December, 2013 at the Bombay Exhibition Centre in Mumbai); CPhI, ICSE, P-MEC, BioPh and Pharmatec Japan ; CPhI Russia and IPhEB (16-17 April, 2014 in St Petersburg, Russia); CPhI, P-MEC and Innopack South East Asia (20-22 May, 2014 in Jakarta, Indonesia); CPhI Istanbul (4-6 June, 2014, Turkey)
The UBM Live annual schedule of Pharmaceutical events also includes CPhI, ICSE and BioPh South America (06-08 August, 2013 at the Expo Center Norte in Sao Paulo, Brazil); CPhI Worldwide, ICSE, P-MEC Europe and InnoPack (22-24 October, 2012 at Messe Frankfurt, Germany; CPhI and P-MEC India (03-05 December, 2013 at the Bombay Exhibition Centre in Mumbai); CPhI, ICSE, P-MEC, BioPh and Pharmatec Japan ; CPhI Russia and IPhEB (16-17 April, 2014); CPhI, P-MEC and Innopack SE Asia (20-22 May, 2014 in Jakarta, Indonesia); CPhI, P-MEC, ISCE, InnoPack Istanbul (4-6 June 1014 in Istanbul) CPhI, P-MEC, ICSE, InnoPack and BioPh China (26-28 June 2014 in Shaghai).
About CPhI
CPhI drives growth and innovation at every step of the global pharmaceutical supply chain from drug discovery to finished dosage. Through exhibitions, conferences and online communities, CPhI brings together more than 100,000 pharmaceutical professionals each year to network, identify business opportunities and expand the global market. CPhI hosts events in Europe, China, India, Japan, Southeast Asia, Russia and South America co-located with ICSE for contract services, P-MEC for machinery, equipment & technology, InnoPack for pharmaceutical packaging and BioPh for biopharma. CPhI provides an online buyer & supplier directory at CPhI-Online.com and hosts a global community with news and analysis at PharmaEvolution.com.
For more information visit: http://www.cphi.com
About UBM Live
UBM Live connects people and creates opportunities for companies across five continents to develop new business, meet customers, launch new products, promote their brands, and expand their market. Through premier brands such as TFM&A, Internet World, IFSEC, MD&M, CPhI, Cruise Shipping Miami, the Concrete Show, and many others, UBM Live exhibitions, conferences, awards programs, publications, Websites, and training and certification programs are an integral part of the marketing plans of companies across more than 20 industry sectors.
For media enquiries, please contact: Alex Heeley or Tristan Jervis De Facto Communications T: +44-(0)207-203-6745 / 6740 E: a.heeley@defacto.com / t.jervis@defacto.com
Photo: http://photos.prnewswire.com/prnh/20130723/629764-a